RU2019133594A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019133594A3 RU2019133594A3 RU2019133594A RU2019133594A RU2019133594A3 RU 2019133594 A3 RU2019133594 A3 RU 2019133594A3 RU 2019133594 A RU2019133594 A RU 2019133594A RU 2019133594 A RU2019133594 A RU 2019133594A RU 2019133594 A3 RU2019133594 A3 RU 2019133594A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164349 | 2017-03-31 | ||
EP17164349.7 | 2017-03-31 | ||
PCT/EP2018/057900 WO2018178141A1 (en) | 2017-03-31 | 2018-03-28 | Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2019133594A RU2019133594A (ru) | 2021-04-30 |
RU2019133594A3 true RU2019133594A3 (ru) | 2021-07-21 |
Family
ID=58464443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019133594A RU2019133594A (ru) | 2017-03-31 | 2018-03-28 | Кристаллическая натриевая соль 5-метил-(6s)-тетрагидрофолиевой кислоты |
Country Status (9)
Country | Link |
---|---|
US (2) | US11185545B2 (ru) |
EP (1) | EP3609894A1 (ru) |
JP (1) | JP7285785B2 (ru) |
KR (1) | KR102665004B1 (ru) |
CN (1) | CN110475778A (ru) |
AU (1) | AU2018246265B2 (ru) |
CA (1) | CA3058287A1 (ru) |
RU (1) | RU2019133594A (ru) |
WO (1) | WO2018178141A1 (ru) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124452A (en) | 1978-07-10 | 1992-06-23 | Bioresearch S.P.A. | Process for producing d,1-5-methyltetrahydrofolic acid and its salts |
IT1229517B (it) | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
CH686369A5 (de) | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
ZA968485B (en) | 1995-11-01 | 1997-05-20 | Lonza Ag | Process for preparing nicotinamide |
CH689831A5 (de) | 1995-11-07 | 1999-12-15 | Eprova Ag | Stabile kristalline Tetrahydrofolsaeure-Salze. |
CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
AU2008351242B2 (en) | 2008-02-20 | 2012-12-20 | Gnosis S.P.A. | Folates, compositions and uses thereof |
WO2013025203A1 (en) * | 2011-08-16 | 2013-02-21 | Watson Laboratories, Inc. | Resolution of tetrahydrofolic acid derivatives |
ITMI20111808A1 (it) * | 2011-10-05 | 2013-04-06 | Ati S R L | Composizione alimentare priva di glutine e prodotti alimentari con essa preparati |
WO2013107236A1 (zh) * | 2012-01-20 | 2013-07-25 | 连云港金康和信药业有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN104557937B (zh) * | 2012-01-20 | 2017-03-08 | 连云港金康和信药业有限公司 | (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法 |
US20160207925A1 (en) * | 2013-12-31 | 2016-07-21 | Gianni Fracchia | L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof |
WO2015193778A1 (en) * | 2014-06-16 | 2015-12-23 | Mylan Laboratories Ltd. | Crystalline form of levomefolate calcium |
-
2018
- 2018-03-28 CN CN201880020919.3A patent/CN110475778A/zh active Pending
- 2018-03-28 US US16/498,549 patent/US11185545B2/en active Active
- 2018-03-28 KR KR1020197031538A patent/KR102665004B1/ko active IP Right Grant
- 2018-03-28 AU AU2018246265A patent/AU2018246265B2/en active Active
- 2018-03-28 RU RU2019133594A patent/RU2019133594A/ru unknown
- 2018-03-28 CA CA3058287A patent/CA3058287A1/en active Pending
- 2018-03-28 JP JP2019553824A patent/JP7285785B2/ja active Active
- 2018-03-28 WO PCT/EP2018/057900 patent/WO2018178141A1/en active Application Filing
- 2018-03-28 EP EP18715594.0A patent/EP3609894A1/en active Pending
-
2021
- 2021-07-28 US US17/387,077 patent/US20220016121A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018246265B2 (en) | 2022-07-07 |
KR20190136029A (ko) | 2019-12-09 |
US20200030333A1 (en) | 2020-01-30 |
US20220016121A1 (en) | 2022-01-20 |
CA3058287A1 (en) | 2018-10-04 |
US11185545B2 (en) | 2021-11-30 |
KR102665004B1 (ko) | 2024-05-09 |
WO2018178141A1 (en) | 2018-10-04 |
EP3609894A1 (en) | 2020-02-19 |
JP7285785B2 (ja) | 2023-06-02 |
RU2019133594A (ru) | 2021-04-30 |
JP2020512383A (ja) | 2020-04-23 |
AU2018246265A1 (en) | 2019-11-14 |
CN110475778A (zh) | 2019-11-19 |